

Alphanate® (Antihemophilic Factor/von Willebrand Factor Complex [Human])

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Alphanate safely and effectively. See full prescribing information for Alphanate.

ALPHANATE (ANTHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN)) sterile, lyophilized powder for injection Initial U.S. Approval: 1978

RECENT MAJOR CHANGES

von Willebrand Disease (for surgical and/or invasive procedures) (1.2) 03/2010

INDICATIONS AND USAGE

Alphanate is an Antihemophilic Factor/von Willebrand Factor Complex (Human) indicated for:

- the prevention and control of bleeding in patients with Factor VIII deficiency due to Hemophilia A or acquired Factor VIII deficiency (1.1)
- for surgical and/or invasive procedures in patients with von Willebrand Disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery (1.2)

DOSAGE AND ADMINISTRATION

Antihemophilic factor potency (Factor VIII:C activity) is expressed in International Units (IU) on the product label. Additionally, each vial of Alphanate also contains VWF:RCo activity in IU for the treatment of VWD (2).

Hemophilia A (2.1)

- As a general rule, dosing requirements and frequency of dosing is calculated on the basis of an expected initial response of 2% of normal FVIII:C increase per FVIII:C IU/kg body weight administered.

von Willebrand Disease (2.2)

- Adults: 40-60 VWF:RCo IU/kg body weight
- Pediatric: 50-75 VWF:RCo IU/kg body weight

DOSAGE FORMS AND STRENGTHS

- Alphanate is a sterile, lyophilized powder for injection, provided in the following potencies: (3)
 - 250 IU FVIII/5 mL single dose vial
 - 500 IU FVIII/5 mL single dose vial
 - 1000 IU FVIII/10 mL single dose vial
 - 1500 IU FVIII/10 mL single dose vial

CONTRAINDICATIONS

- None known (4)

WARNINGS AND PRECAUTIONS

- Thromboembolic events associated with AHF/VWF products (5.1)
- Theoretical risk of infectious agents transmission as the product is made from human plasma (5.2)
- Factor VIII antibodies (inhibitors) and alloantibodies to VWF (5.3)
- Symptoms and signs of hypersensitivity reaction (5.4)

ADVERSE REACTIONS

The most common adverse reactions include: urticaria, fever, chills, nausea, vomiting, headache, somnolence, or lethargy (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- None known (7)

USE IN SPECIFIC POPULATIONS

- Unknown whether can cause fetal harm or affect reproduction capacity (8.1)
- Clinical trials for safety and effectiveness in pediatric Hemophilia A patients have not been conducted (8.4).

See 17 for PATIENT COUNSELING INFORMATION

Revised: 03/2010

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Hemophilia A or Acquired Factor VIII Deficiency
- 1.2 von Willebrand Disease

2 DOSAGE AND ADMINISTRATION

- 2.1 Hemophilia A
- 2.2 von Willebrand Disease
- 2.3 Reconstitution

3 DOSAGE FORMS AND STRENGTH

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Thromboembolic Events
- 5.2 Infections
- 5.3 Inhibitor Formation
- 5.4 Information for Patients

6 ADVERSE REACTIONS

- 6.1 General
- 6.2 Adverse Reactions in VWD Patients from Clinical Studies
- 6.3 Adverse Reaction Information from Spontaneous Reports

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.4 Pediatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

14 CLINICAL STUDIES

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

- 17.1 Thromboembolic Events
- 17.2 Infections
- 17.3 Inhibitor Formation

* Sections or subsections omitted from the full prescribing information are not listed.

1. INDICATIONS AND USAGE

1.1 Hemophilia A or Acquired Factor VIII Deficiency

Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate®, is indicated for the prevention and control of bleeding in patients with Factor VIII deficiency due to hemophilia A or acquired Factor VIII deficiency.¹

1.2 von Willebrand Disease

Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate®, is also indicated for surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin (DDAVP®) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery.

2. DOSAGE AND ADMINISTRATION

Following reconstitution with the supplied diluent, Alphanate® should be administered intravenously within three hours after reconstitution to avoid the potential ill effect of any inadvertent bacterial contamination occurring during reconstitution. Alphanate® is administered by injection (plastic disposable syringes are recommended). Administer at room temperature, do not refrigerate after reconstitution, and discard any unused contents into the appropriate safety container.

Antihemophilic Factor (AHF) potency (Factor VIII:C activity) is expressed in International Units (IU) on the product label. Additionally, each vial of Alphanate® also contains von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) activity in IU for the treatment of VWD.

2.1 Hemophilia A

Dosing requirements and frequency of dosing is calculated on the basis of an expected initial response of 2% of normal FVIII:C increase per FVIII:C IU/kg body weight administered.^{2,3} The *in vivo* increase in plasma Factor VIII can therefore be estimated by multiplying the dose of AHF per kilogram of body weight (FVIII:C IU/kg) by 2%. Thus, an administered AHF dose of 50 IU/kg will be expected to increase the circulating Factor VIII level by 100% of normal (100 IU/dL). The following formulas and examples illustrate these principles:

$$a) \text{ Expected plasma Factor VIII:C increase (\% normal)} = \frac{\text{Number of FVIII:C IU administered}}{\text{body weight (kg)}} \times 2\% \text{ IU/kg}$$

Example: A 70 kg adult administered AHF 2100 IU:

$$\text{Plasma FVIII:C increase (\% normal)} = \frac{2100 \text{ IU}}{70 \text{ kg}} \times 2\% \text{ IU/kg} = 60\% \text{ normal plasma FVIII:C level}$$

$$b) \text{ Dosage required (IU)} = \frac{\text{desired plasma Factor VIII increase (\% normal)} \times \text{body weight (kg)}}{2\% \text{ IU/kg}}$$

Example: A 15 kg child with a baseline plasma FVIII level of 0%. To increase the plasma Factor VIII concentration to 100% of normal, the dosage required is as follows:

$$\text{Dosage required (IU)} = \frac{100\%}{2\% \text{ IU/kg}} \times 15 \text{ kg} = 50 \text{ IU/kg} \times 15 \text{ kg} = 750 \text{ IU}$$

The following dosages are presented as general guidance. It should be emphasized that the dosage of Alphanate® required for hemostasis must be individualized according to the needs of the patient, the severity of the deficiency, the severity of the hemorrhage, the presence of inhibitors, and the FVIII level desired. Adequacy of treatment must be judged by the clinical effects and situation and thus, the dosage may vary with individual cases.

Table 1: Dosage Guidelines for the Treatment of Hemophilia A

Hemorrhagic event	Dosage (AHF FVIII:C IU/kg Body Weight)
Minor hemorrhage: <ul style="list-style-type: none">• Bruises• Cuts or scrapes• Uncomplicated joint hemorrhage	FVIII:C levels should be brought to 30% of normal (15 FVIII IU/kg twice daily) until hemorrhage stops and healing has been achieved (1-2 days).
Moderate hemorrhage: <ul style="list-style-type: none">• Nose, mouth and gum bleeds• Dental extractions• Hematuria	FVIII:C levels should be brought to 50% (25 FVIII IU/kg twice daily). Treatment should continue until healing has been achieved (2-7 days, on average).
Major hemorrhage: <ul style="list-style-type: none">• Joint hemorrhage• Muscle hemorrhage• Major trauma• Hematuria• Intracranial and intraperitoneal bleeding	FVIII:C levels should be brought to 80-100% for at least 3-5 days (40-50 FVIII IU/kg twice daily). Following this treatment period, FVIII levels should be maintained at 50% (25 FVIII IU/kg twice daily) until healing has been achieved. Major hemorrhages may require treatment for up to 10 days.
Surgery	Prior to surgery, the levels of FVIII:C should be brought to 80-100% of normal (40-50 FVIII IU/kg). For the next 7-10 days, or until healing has been achieved, the patient should be maintained at 60-100% FVIII levels (25-50 FVIII IU/kg twice daily).

Dosing requirements and frequency of dosing is calculated on the basis of an expected initial response of 2% FVIII:C increase per FVIII:C IU/kg body weight (i.e., 2% per IU/kg) and an average half-life for FVIII:C of 12 hours.^{4,5} If dosing studies have determined that a particular patient exhibits a lower than expected response, the dose should be adjusted accordingly. Failure to achieve the expected plasma FVIII:C level or to control bleeding after an appropriately calculated dosage may be indicative of the development of an inhibitor (an antibody to FVIII:C). Its presence should be documented and the inhibitor level quantitated by appropriate laboratory procedures. Treatment with AHF in such cases must be individualized.⁶⁻⁸

Plasma factor VIII levels should be monitored periodically to evaluate individual patient response to the dosage regime.

2.2 von Willebrand Disease

The following table provides dosing guidelines for pediatric and adult patients with von Willebrand Disease.⁹⁻¹²

The amount of VWF:RCo and Factor VIII contained in each vial of Alphanate® is indicated on the vial's label. The ratio of VWF:RCo to Factor VIII in Alphanate® varies by lot, so dosage should be re-evaluated whenever lot selection is changed.

Table 2: Dosage Guidelines for the Prophylaxis During Surgery and Invasive Procedure of von Willebrand Disease (Except Type 3 Subjects Undergoing Major Surgery)


Bleeding Prophylaxis for Surgical or Invasive Procedures	Dosage (AHF VWF:RCo IU/kg Body Weight)
Adult	Pre-operative dosage: 60 VWF:RCo IU/kg body weight. Subsequent infusions: 40 to 60 VWF:RCo IU/kg body weight at 8 to 12 hour intervals as clinically needed. Dosing may be reduced after the third postoperative day. Continue treatment until healing is complete.
	Minor procedure: VWF activity of 40%-50% during 1 to 3 days postoperative.
	Major procedure: VWF activity of 40%-50% during at least 3 to 7 days postoperative.
Pediatric	Initial dosage: 75 VWF:RCo IU/kg body weight. Subsequent infusions: 50 to 75 VWF:RCo IU/kg body weight at 8 to 12 hour intervals as clinically needed. Dosing may be reduced after the third postoperative day. Continue treatment until healing is complete.

2.3 Reconstitution

Always Use Aseptic Technique

1. Warm diluent (Sterile Water for Injection, USP) and concentrate (Alphanate®) to at least room temperature (but not above 37 °C).
2. Remove the plastic flip off cap from the diluent vial.
3. Gently swab the exposed stopper surface with a cleansing agent such as alcohol trying to avoid leaving any excess cleansing agent on the stopper.
4. Open the Mix2Vial™ package by peeling away the lid (Figure 1). Leave the Mix2Vial™ in the clear outer packaging.
5. Place the diluent vial upright on an even surface and hold the vial tight and pick up the Mix2Vial™ in its clear outer packaging. Holding the diluent vial securely, push the blue end of the Mix2Vial™ vertically down through the diluent vial stopper (Figure 2).

- While holding onto the diluent vial, carefully remove the clear outer packaging from the Mix2Vial™ set, ensuring the Mix2Vial™ remains attached to the diluent vial (Figure 3).
- Place the product vial upright on an even surface, invert the diluent vial with the Mix2Vial™ attached.
- While holding the product vial securely on a flat surface, push the clear end of the Mix2Vial™ set vertically down through the product vial stopper (Figure 4). The diluent will automatically transfer out of its vial into the product vial. (NOTE: If the Mix2Vial™ is connected at an angle, the vacuum may be released from the product vial and the diluent will not transfer into the product vial.)
- With the diluent and product vials still attached to the Mix2Vial™, gently swirl the product vial to ensure the product is fully dissolved (Figure 5). Reconstitution requires less than 5 minutes. Do not shake the vial.
- Disconnect the Mix2Vial™ into two separate pieces (Figure 6) by holding each vial adapter and twisting counterclockwise. After separating, discard the diluent vial with the blue end of the Mix2Vial™.
- Draw air into an empty, sterile syringe. Keeping the product vial upright with the clear end of the Mix2Vial™ attached, screw the disposable syringe onto the luer lock portion of the Mix2Vial™ device by pressing and twisting clockwise. Inject air into the product vial.
- While keeping the syringe plunger depressed, invert the system upside down and draw the reconstituted product into the syringe by pulling the plunger back slowly (Figure 7).
- When the reconstituted product has been transferred into the syringe, firmly hold the barrel of the syringe and the clear vial adapter (keeping the syringe plunger facing down) and unscrew the syringe from the Mix2Vial™ (Figure 8). Hold the syringe upright and push the plunger until no air is left in the syringe. Attach the syringe to a venipuncture set.
- NOTE: If the same patient is to receive more than one vial of concentrate, the contents of two vials may be drawn into the same syringe through a separate unused Mix2Vial™ set before attaching to the venipuncture set.
- Use prepared drug as soon as possible after reconstitution.
- After reconstitution, parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. When reconstitution procedure is strictly followed, a few small particles may occasionally remain. The Mix2Vial™ set will remove particles and the labeled potency will not be reduced.
- Discard all administration equipment after use into the appropriate safety container. Do not reuse.



3. DOSAGE FORMS AND STRENGTHS

Alphanate® is a sterile, lyophilized powder for injection. It is available in the following potencies:

- 250 IU FVIII/5 mL single dose vial
- 500 IU FVIII/5 mL single dose vial
- 1000 IU FVIII/10 mL single dose vial
- 1500 IU FVIII/10 mL single dose vial

4. CONTRAINDICATIONS

None.

5. WARNINGS AND PRECAUTIONS

5.1 Thromboembolic Events

Thromboembolic events have been reported in von Willebrand Disease patients receiving Antihemophilic Factor/von Willebrand Factor Complex replacement therapy, especially in the setting of known risk factors for thrombosis.^{13,14} Early reports might indicate a higher incidence in females. In addition, endogenous high levels of FVIII have also been associated with thrombosis but no causal relationship has been established. In all VWD patients in situations of high thrombotic risk receiving coagulation factor replacement therapy, caution should be exercised and antithrombotic measures should be considered. See also **ADVERSE REACTIONS (6.1) and PATIENT COUNSELING INFORMATION (17.1).**

5.2 Infections

Because Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate® is made from pooled human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Stringent procedures designed to reduce the risk of adventitious agent transmission have been employed in the manufacture of this product, from the screening of plasma donors and the collection and testing of plasma, through the application of viral elimination/reduction steps such as solvent detergent and heat treatment in the manufacturing process. Despite these measures, such products can still potentially transmit disease; therefore, the risk of infectious agents cannot be totally eliminated. The physician should weigh the risks and benefits of the use of this product and should discuss these with the patient. See also **PATIENT COUNSELING INFORMATION (17.2).**

Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly hepatitis C.^{15,16} Incubation in a solvent detergent mixture during the manufacturing process is designed to reduce the risk of transmitting viral infection.^{15,16} However, medical opinion encourages hepatitis A and hepatitis B vaccinations for patients with hemophilia at birth or at the time of diagnosis.

Nursing personnel, and others who administer this material, should exercise appropriate caution when handling due to the risk of exposure to viral infection.

5.3 Inhibitor Formation

Rapid administration of a Factor VIII concentrate may result in vasomotor reactions. Alphanate® should not be administered at a rate exceeding 10 mL/minute.

Some patients develop inhibitors to Factor VIII. These inhibitors are circulating antibodies (i.e., globulins) that neutralize the procoagulant activity of Factor VIII. No studies have been conducted with Alphanate® to evaluate inhibitor formation. Therefore, it is not known whether there are greater, lesser or the same risks of developing inhibitors due to the use of this product than there are with other antihemophilic factor preparations. Patients with these inhibitors may not respond to treatment with Antihemophilic Factor/von Willebrand Factor Complex (Human), or the response may be much less than would otherwise be expected; therefore, larger doses of Antihemophilic Factor/von Willebrand Factor Complex (Human) are often required. The management of bleeding in patients with inhibitors requires careful monitoring, especially if surgical procedures are indicated.^{6,8} See also **PATIENT COUNSELING INFORMATION (17.3).**

Reports in the literature suggest that patients with Type 3, severe von Willebrand Disease, may occasionally develop alloantibodies to von Willebrand factor after replacement therapy.¹⁷ The risk of developing alloantibodies in patients with von Willebrand disease due to the use of this product is not known.

Unused contents should be discarded into the appropriate safety container. Administration equipment should be discarded after single use into the appropriate safety container. Components should not be re-sterilized.

5.4 Information for Patients

Patients should be informed of the early symptoms and signs of hypersensitivity reaction, including hives, generalized urticaria,

chest tightness, dyspnea, wheezing, faintness, hypotension, and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician and/or seek immediate emergency care, depending on the severity of the reaction, if these symptoms occur.

Patients should be informed of a potential for viral infection such as parvovirus B19 or hepatitis A. Parvovirus B19 may most seriously affect seronegative pregnant women, or immunocompromised individuals. Patients should report any signs and symptoms of fever, sore throat, or joint soreness to the physician immediately.

6. ADVERSE REACTIONS

6.1 General

The most common adverse reactions may include urticaria, fever, chills, nausea, vomiting, headache, somnolence, or lethargy. Occasionally, mild reactions occur following the administration of Antihemophilic Factor/von Willebrand Factor Complex (Human), such as allergic reactions, chills, nausea, or stinging at the infusion site.⁴ If a reaction is experienced, and the patient requires additional Antihemophilic Factor/von Willebrand Factor Complex (Human), product from a different lot should be administered. Massive doses of Antihemophilic Factor/von Willebrand Factor Complex (Human) have rarely resulted in acute hemolytic anemia, increased bleeding tendency or hyperfibrinogenemia.⁵ Alphanate® contains blood group specific isoagglutinins and, when large and/or frequent doses are required in patients of blood groups A, B, or AB, the patient should be monitored for signs of intravascular hemolysis and falling hematocrit. Should this condition occur, thus leading to progressive hemolytic anemia, the administration of serologically compatible Type O red blood cells should be considered, the administration of Alphanate® should be discontinued, and alternative therapy should be considered.

Reports of thromboembolic events in VWD patients with other thrombotic risk factors receiving coagulation factor replacement therapy have been obtained from published literature. Early reports might indicate a higher incidence in females. Caution should be exercised and antithrombotic measures should be considered in all VWD patients in situations of high thrombotic risk. See **WARNINGS AND PRECAUTIONS (5.1).**

6.2 Adverse Reactions in VWD Patients from Clinical Studies

In clinical studies of Alphanate® (A-SD/HT) in patients with VWD, adverse reactions occurred in 6 of 38 (15.8%) subjects and 17 of 299 (5.7%) infusions. The most common adverse events were pruritus, pharyngitis (throat tightness), paresthesia and headache, edema of the face, rash and chills. Except for one instance of pruritus, which was considered moderate in severity, all the adverse events were assessed as mild in severity.

A single incident of pulmonary embolus was reported that was considered to have a possible relationship to the product. This subject received the dose of 60 VWF:RCo IU/kg body weight and the FVIII:C level achieved was 290%.⁶

In the retrospective study, 3 out of 39 subjects (7.7%) experienced 6 adverse drug reactions. Four were considered mild and 2 were considered moderate; and no subject discontinued their treatment due to an adverse reaction. The adverse drug reactions were pruritus, paresthesia (2 events) and hemorrhage (all considered mild), and one event each of moderate hematocrit decrease and orthostatic hypotension.

Only one adverse event (pain) related to the treatment with heat-treated Alphanate® (A-SD/HT) was reported on the four pediatric patients with von Willebrand Disease during the course of the prospective study and none of the five subjects in the retrospective clinical study.¹⁸

6.3 Adverse Reaction Information from Spontaneous Reports

The following adverse reactions have been identified during post-approval use of Alphanate® (A-SD/HT). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These adverse reactions have been reported as swelling of the parotid gland, urticaria, nausea, shortness of breath, chest tightness, chills, fever, rigors, headache, flushing, vomiting, joint pain, seizure, pulmonary embolus, femoral venous thrombosis, itching and cardiorespiratory arrest.

To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals Inc. at 1-888-GRIFOLS (1-888-474-3657) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

7. DRUG INTERACTIONS

None known.

8. USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Alphanate®. It is also not known whether Alphanate® can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. Alphanate® should be given to a pregnant woman only if clearly needed.

8.2 Pediatric Use

8.2.1 Hemophilia A Indication

Clinical trials for safety and effectiveness in pediatric Hemophilia A patients 16 years of age and younger have not been conducted. During a well controlled half-life and recovery clinical trial in patients previously treated with Factor VIII concentrates for Hemophilia A, the single pediatric patient receiving Alphanate® (solvent detergent non-heat treated) responded similarly when compared with 12 adult patients.¹⁹ No adverse events were reported in either pediatric or adult patients with Alphanate®.

8.2.2 VWD Indication

Fifteen pediatric patients with von Willebrand Disease younger than 18 years of age were treated with non-heat (A-SD) and heat-treated (A-SD/HT) Alphanate® during the course of clinical studies.¹⁸ In the retrospective study, five patients younger than 18 years of age were treated with heat-treated (A-SD/HT) Alphanate®.

11. DESCRIPTION

Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate® sterile, lyophilized concentrate of Factor VIII (AHF) and von Willebrand Factor (VWF), is intended for intravenous administration in the treatment of hemophilia A, acquired Factor VIII deficiency, and von Willebrand Disease (VWD).

Alphanate® is prepared from pooled human plasma by cryoprecipitation of Factor VIII, fractional solubilization, and further purification employing heparin-coupled, cross-linked agarose which has an affinity to the heparin binding domain of VWF/FVIII:C complex.¹⁹ The product is treated with a mixture of tri-n-butyl phosphate (TNBP) and polysorbate 80 to reduce the risks of transmission of viral infection. In order to provide an additional safeguard against potential non-lipid enveloped viral contaminants, the product is also subjected to an 80 °C heat treatment step for 72 hours. However, no procedure has been shown to be totally effective in removing viral infectivity from coagulation factor products.

Alphanate® is labeled with the antihemophilic factor potency (Factor VIII:C activity) in International Units (IU) per vial. Each vial of Alphanate® also contains the labeled amount of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) activity expressed in IU. An IU is defined by the current international standard established by the World Health Organization. One IU of Factor VIII or one IU of VWF:RCo is approximately equal to the amount of Factor VIII or VWF:RCo in 1 mL of freshly-pooled human plasma.

Alphanate® contains Albumin (Human) as a stabilizer, resulting in a final container concentrate with a specific activity of at least 5 FVIII:C IU/mg total protein. Prior to the addition of the Albumin (Human) stabilizer, the specific activity is significantly higher.

When reconstituted as directed, the composition of Alphanate® is as follows:

Component	Concentration
Factor VIII:C activity	40 - 180 IU/mL
VWF:RCo activity	NLT 0.4 VWF:RCo IU per 1 IU of FVIII:C
Albumin (Human)	0.3 - 0.9 g/100 mL
Calcium	NMT 5 mmol/L
Glycine	NMT 750 µg per FVIII:C IU
Heparin	NMT 1.0 U/mL
Histidine	10 - 40 mmol/L
Imidazole	NMT 0.1 mg/mL
Arginine	50 - 200 mmol/L
Polyethylene Glycol and Polysorbate 80	NMT 1.0 µg per FVIII:C IU
Sodium	NMT 10 mEq/vial
Tri-n-butyl Phosphate (TNBP)	NMT 0.1 µg per FVIII:C IU

NMT = not more than

NLT = not less than

Viral Reduction Capacity

The solvent detergent treatment process has been shown by Horowitz, et al., to provide a high level of viral inactivation without compromising protein structure and function.²⁰ The susceptibility of human pathogenic viruses such as Human Immunodeficiency viruses (HIV), hepatitis viruses, as well as marker viruses such as Sindbis virus (SIN, a model for Hepatitis C virus) and Vesicular Stomatitis virus (VSV, a model for large, enveloped RNA virus), to inactivation by organic solvent detergent treatment has been discussed in the literature.²¹

In vitro inactivation studies to evaluate the solvent detergent treatment (0.3% Tri-n-butyl Phosphate and 1.0% Polysorbate 80) step in the manufacture of Alphanate® demonstrated a log inactivation of ≥ 11.1 for HIV-1, ≥ 6.1 for HIV-2, ≥ 4.1 for VSV and \geq

4.7 for SIN. Since the number of virus particles inactivated by the process represents the maximum amount of virus added initially to the sample, these results indicate that all the virus added was killed to the assay limit of detection.¹⁵

Additional steps in the manufacturing process of Alphanate[®] were evaluated for virus elimination capability. The dry heat cycle of 80 °C for 72 hours was shown to inactivate greater than 5.8 logs of Hepatitis A virus (HAV).¹⁵ Precipitation with 3.5% polyethylene glycol (PEG) and heparin-actigel-ALD chromatography are additional steps studied using Bovine Herpes virus (BHV, a model for Hepatitis B virus), Bovine Viral Diarrhea virus (BVD, a second model for Hepatitis C virus), human Poliovirus Sabin type 2 (POL, a model for Hepatitis A virus), Canine Parvovirus (CPV, a model for Parvovirus B19) and HIV-1.

Table 3 summarizes the reduction factors for each virus validation study performed for the manufacturing process of Alphanate[®].¹⁵ It must be stated that no treatment method has yet been shown capable of totally eliminating all potential infectious virus in preparations of coagulation factor concentrates.

Table 3: Virus Log Reduction

Virus (Model Virus for)	3.5% PEG Precipitation	Solvent-Detergent	Column Chromatography	Lyophilization	Dry Heat Cycle (80 °C, 72 h)	Total Log Removal
BHV (HBV)	< 1.0	≥ 8.0	7.6	1.3	2.1	≥ 19.0
BVD (HCV)	< 1.0	≥ 4.5	< 1.0	< 1.0	≥ 4.9	≥ 9.4
POL (HAV)	3.3	–	< 1.0	3.4	≥ 2.5	≥ 9.2
CPV (B19)	1.2	–	< 1.0	< 1.0	4.1	5.3
VSV	–	≥ 4.1	–	–	–	≥ 4.1
SIN (HCV)	–	≥ 4.7	–	–	–	≥ 4.7
HIV-1	< 1.0	≥ 11.1	≥ 2.0	–	–	≥ 13.1
HIV-2	–	≥ 6.1	–	–	–	≥ 6.1
HAV	–	–	–	2.1	≥ 5.8	≥ 7.9

12. CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Antihemophilic Factor/von Willebrand Factor Complex (Human) (Factor VIII) and von Willebrand Factor (VWF) are constituents of normal plasma and are required for clotting. The administration of Alphanate[®] temporarily increases the plasma level of Factor VIII, thus minimizing the hazard of hemorrhage.^{22,23} Factor VIII is an essential cofactor in activation of Factor X leading to formation of thrombin and fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; it also serves as a stabilizing carrier protein for the procoagulant protein Factor VIII.^{24,25}

12.2 Pharmacokinetics

12.2.1 Pharmacokinetics in Hemophilia A

Following the administration of Alphanate[®] during clinical trials, the mean *in vivo* half-life of Factor VIII observed in 12 adult subjects with severe hemophilia A was 17.9 ± 9.6 hours. In this same study, the *in vivo* recovery was 96.7 ± 14.5% at 10 minutes postinfusion.¹⁸ Recovery at 10 minutes post-infusion was also determined as 2.4 ± 0.4 IU FVIII rise/dL plasma per IU FVIII infused/kg body weight.¹⁸

12.2.2 Pharmacokinetics in von Willebrand Disease (VWD)

A pharmacokinetic crossover study was conducted in 14 non-bleeding subjects with VWD (1 type 1, 2 type 2A, and 11 type 3) comparing the pharmacokinetics of Alphanate[®] SD/HT (A-SD/HT) and an earlier formulation, Alphanate[®] SD (A-SD), which was treated with solvent-detergent but was not heat-treated.¹⁸ Subjects received, in random order at least seven days apart, a single intravenous dose each of A-SD and A-SD/HT, 60 VWF:RCo IU/kg (75 VWF:RCo IU/kg in subjects younger than 18 years of age). Pharmacokinetic parameters were similar for the two preparations and indicated that they were biochemically equivalent. Pharmacokinetic analysis of A-SD/HT in the 14 subjects revealed the following results¹⁸: the median plasma levels of VWF:RCo rose from 0.17 IU/dL [mean, 0.2 ± 0.08 IU/dL; range: 0.1 to 0.5 IU/dL] at baseline to 3.43 IU/dL [mean, 3.5 ± 1.47 IU/dL; range: 1.5 to 5.9 IU/dL] 15 minutes post-infusion; median plasma levels of FVIII:C rose from 0.08 IU/dL [mean, 0.2 ± 0.34 IU/dL; range: 0.0 to 1.2 IU/dL] to 2.14 IU/dL [mean, 2.4 ± 0.72 IU/dL; range: 1.4 to 3.9 IU/dL]. The median bleeding time (BT) prior to infusion was 30 minutes (mean, 28.8 ± 4.41 minutes; range: 13.5 to 30 minutes), which shortened to 10.38 minutes (mean, 10.4 ± 3.20 minutes; range: 6 to 16 minutes) 1 hour post-infusion.

Following infusion of A-SD/HT, the median half-lives for VWF:RCo, FVIII:C and VWF:Ag were 6.91 hours (mean, 7.46 ± 3.20 hours, range, 3.68 to 16.22 hours), 20.87 hours (mean, 21.52 ± 7.21 hours; range: 7.19 to 32.20 hours), and 12.66 hours (mean, 13.03 ± 2.12 hours; range: 10.34 to 17.45 hours), respectively. The median incremental *in vivo* recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [mean, 3.29 ± 1.46 (IU/dL)/(IU/kg); range: 1.3 to 5.7 (IU/dL)/(IU/kg)] for VWF:RCo and 1.94 (IU/dL)/(IU/kg) [mean, 2.14 ± 0.58 (IU/dL)/(IU/kg); range: 1.3 to 3.3 (IU/dL)/(IU/kg)] for FVIII:C.

Following infusion of both A-SD and A-SD/HT, an increase in the size of VWF multimers was seen and persisted for at least 24 hours. The shortening of the BT was transient, lasting less than 6 hours following treatment and did not correlate with the presence of large and intermediate size VWF multimers.²⁵

14. CLINICAL STUDIES

Prophylaxis for Elective Surgery

Thirty seven subjects with VWD (6 Type 1, 16 Type 2A, 3 Type 2B, 12 Type 3) underwent 59 surgical procedures that included 20 dental, 7 orthopedic, 8 gastrointestinal, 6 gastrointestinal (diagnostic), 9 vascular, 3 gynecologic, 2 genitourinary, 2 dermatologic and 2 head and neck procedures administering A-SD or A-SD/HT (21 subjects were administered A-SD and 18 were administered A-SD/HT, 2 received both products) for bleeding prophylaxis (see **Table 4**). Prior to each surgical procedure, the investigators provided an estimation of the expected blood loss during surgery for a normal person of the same sex and of similar stature and age as the subject undergoing the same type of surgical procedure. An initial preoperative infusion of 60 VWF:RCo IU/kg (75 VWF:RCo IU/kg for patients less than 18 years of age), was administered one hour preoperatively. A sample was obtained 15 minutes after the initial infusion for the determination of the plasma FVIII:C level. The level had to equal or exceed 100% of normal for an operation to proceed. No cryoprecipitate or alternative FVIII product was administered during these surgical procedures. Platelets were required in only two subjects. Intra-operative infusions of A-SD and A-SD/HT at 60 VWF:RCo IU/kg (75 VWF:RCo IU/kg for patients less than 18 years of age) was administered according to the judgment of the investigator.

Table 4. Number of and Types of Surgical Procedures

Type of Surgical Procedure	Treatment		
	A-SD	A-SD/HT	Total
Number of Subjects	21	18	37 [^]
Dental	14	6	20
Dermatologic	1	1	2
Gastrointestinal	4	4	8
Gastrointestinal (diagnostic)	6	0	6
Genitourinary	0	2	2
Gynecologic	2	1	3
Head and neck	1	1	2
Orthopedic	4	3	7
Vascular	3	6	9
Total number of procedures	35	24	59

[^] Two patients received both preparations; the total number of subjects is therefore less than the sum of the columns.

Postoperative infusions at doses of 40 to 60 VWF:RCo IU/kg (50 to 75 VWF:RCo IU/kg for pediatric patients) was administered at 8- to 12-hour intervals until healing had occurred. After achieving primary hemostasis, for maintenance of secondary hemostasis the dose was reduced after the third postoperative day. See **DOSE AND ADMINISTRATION (2.2)**.

Overall, in 55 surgical procedures undertaken with a prolonged BT pre-infusion, the BT at 30 minutes post-infusion was fully corrected in 18 (32.7%) cases, partially corrected in 24 (43.6%) cases, demonstrated no correction in 12 (21.8%) cases, and was not done in one case (1.8%).

The mean blood loss was lower than predicted prospectively. Bleeding exceeding the predicted value did not correlate with correction of the BT. Three patients had bleeding which exceeded by more than 50 mL the amount predicted prospectively. Among the latter subjects, the BT 30 minutes post-infusion was normal in one and only slightly lengthened in two cases.

Surgical infusion summary data are included in **Table 5**.

Table 5: Prophylaxis with A-SD and/or A-SD/HT in Surgery

	A-SD	A-SD/HT	Total
Number of patients	21	18	37*
Number of surgical procedures	35	24	59
Median number of infusions per surgical procedure (range)	3 (1-13)	4 (1-18)	4 (1-18)
Median dosage VWF:RCo IU/kg			
Infusion #1 (range)	59.8 (19.8-75.1)	59.9 (40.6-75.0)	59.9 (19.8-75.1)
Infusion ≥ 2 combined (range)	40.0 (4.5-75.1)	40.0 (10.0-63.1)	40.0 (4.5-75.1)

* Two subjects received both products

Additionally, the surgeries were categorized as major, minor or invasive procedures according to definitions used in the study. The outcome of each surgery was evaluated according to a clinical rating scale (excellent, good, poor or none) and was considered successful if the outcome was excellent or good. These outcomes are presented in **Table 6**.

Table 6. Effect of Treatment on Surgical Prophylaxis (Investigator Evaluation): Analysis per Treated Event (A-SD/HT)

Investigator's Outcome Evaluation	Type of von Willebrand Disease											
	Type 1 (4 Subjects, 4 Procedures)			Type 2 (9 Subjects, 13 Procedures)			Type 3 (5 Subjects, 7 Procedures)			Total (18 Subjects, 24 Procedures)		
	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	Procedure	
	1	2	3	1	2	3	1	2	3	1	2	3
Excellent	1	0	2	5	1	5	5	0	1	11	1	8
Good	0	0	1	0	0	1	0	0	0	0	0	2
Poor	0	0	0	0	0	0	0	0	0	0	0	0
None	0	0	0	0	1	0	0	1	0	0	2	0

Procedure: 1=Minor, 2=Major, 3=Invasive

Absolute frequency & proportion of successful outcomes = 22/24 (91.66%)

95% Confidence Interval (CI) for the proportion of subjects with successful prophylaxis = 0.7300 to 0.9897

The study results were also evaluated independently by two referees with clinical experience in this field in the same way (surgery categorization and outcome of each surgery according to a clinical rating scale).

The results for the effect of treatment on surgical prophylaxis (Referee Evaluation) per treated subject are summarized in **Table 7**. There is a high level of agreement between the referee evaluations and the analyzed outcome data, with a decrease of only a single success (21/24 vs. 22/24).

Table 7. Effect of Treatment on Surgical Prophylaxis (Referee Evaluation): Analysis per Treated Event (A-SD/HT)

	Referee 1	Referee 2
Number of Treated Subjects	18	18
Number of Treated Events	24	24
Success Absolute Frequency & Proportion (%)	22 (0.9166)	21 (0.8750)
* 95% CI for the Proportion	0.7300 to 0.9897	0.6763 to 0.9734

* 95% confidence interval for the proportion of subjects with successful prophylaxis, exact estimation.

A retrospective study was performed to assess the efficacy of Alphanate[®] (A-SD/HT) as replacement therapy in preventing excessive bleeding in subjects with congenital VWD undergoing surgical or invasive procedures, for whom DDAVP[®] was ineffective or inadequate. The study was performed between September 2004 and December 2005, and 61 surgeries/procedures (in 39 subjects) were evaluated.

Of the 39 subjects, 18 had Type 1 VWD (46.2%); 12 subjects (30.8%) had Type 2 VWD, and 9 subjects (23.1%) had Type 3 VWD. The median age for subjects overall was 40 years; approximately one-half of the subjects overall were male.

The primary efficacy variable was the overall treatment outcome for each surgical or invasive procedure, as rated by the investigator using a 4-point verbal rating scale (VRS): "excellent," "good," "poor," or "none." The categorization of the replacement treatment outcome according to the proposed scale was based upon the investigator's clinical experience.

The secondary efficacy variables were:

- Daily (Day 0 and Day 1) treatment outcome for each surgical or invasive procedure, rated by the investigator using the same 4-point VRS used for the primary efficacy variable. Day 0 was the day of surgery, and Day 1 was the day following surgery.
- Overall treatment outcome for each surgical or invasive procedure, rated by an independent referee committee using the same 4-point VRS used for the primary efficacy variable.

In addition, an independent referee committee was convened to evaluate the efficacy outcomes. The committee was composed of 2 physicians with demonstrated clinical expertise treating subjects with similar medical characteristics to those of the study population. The committee was blinded to the investigator ratings; and each referee evaluated the outcomes independent of one another.

More than 90% received an investigator and referee's overall and daily rating of "effective" ("excellent" or "good"). The results of the primary efficacy analysis are in **Table 8**.

Table 8. Proportion of Procedures (N = 61) With an Overall Investigator Rating of Effective versus Non-effective

Outcome of Alphanate [®] Treatment	Proportion of Procedures (%)	95% Confidence Interval	P Value ^a
Effective ^b	95.1	87.8 - 98.6	
Non-effective ^c	4.9	1.4 - 12.2	< 0.0001

^a Binomial test (H₀: < 70% of procedures have an overall rating of effective).

^b Effective = Investigator rating of "excellent" or "good."

^c Non-effective = Investigator rating of "poor" or "none."

The results of the analysis of daily investigator ratings are in **Table 9**.

Table 9. Proportion of Procedures (N = 61) With a Daily Investigator Rating of Effective versus Non-effective

Study Day ^a	Outcome of Alphanate [®] Treatment	Proportion of Procedures (%)	95% Confidence Interval	P Value ^b
0	Effective ^c	95.1	87.8 - 98.6	< 0.0001
	Non-effective ^d	4.9	1.4 - 12.2	
1	Effective	91.8	83.5 - 96.7	< 0.0001
	Non-effective	8.2	3.3 - 16.5	

^a Study Day 0 = day of surgery.

^b Binomial test (H_0 : < 70% of procedures have an overall rating of effective).

^c Effective = Investigator rating of "excellent" or "good."

^d Non-effective = Investigator rating of "poor" or "none."

The results of the analysis of overall referee ratings are in **Table 10**.

Table 10. Proportion of Procedures (N = 61) With an Overall Referee Rating of Effective versus Non-effective

Outcome of Alphanate [®] Treatment	Proportion of Procedures (%)	95% Confidence Interval	P Value ^a
Effective ^b	91.8	83.5 - 96.7	< 0.0001
Non-effective ^c	8.2	3.3 - 16.5	

^a Binomial test (H_0 : < 70% of procedures have an overall rating of effective).

^b Effective = Referee rating of "excellent" or "good."

^c Non-effective = Referee rating of "poor" or "none."

The overall investigator ratings are summarized by type of VWD in **Table 11**.

Table 11. Number (%) of Investigator's Overall Efficacy Ratings by Type of VWD

Investigator's Overall Rating	Type of von Willebrand Disease							
	Type 1 (18 Subjects, 22 Procedures)		Type 2 (12 Subjects, 23 Procedures)		Type 3 (9 Subjects, 16 Procedures)		Total (39 Subjects, 61 Procedures)	
	Major	Minor ^a	Major	Minor	Major	Minor	Major	Minor
Excellent	6 (85.7%)	12 (80.0%)	2 (50.0%)	18 (94.7%)	0 (0.0%)	13 (86.7%)	8 (66.7%)	43 (87.8%)
Good	1 (14.3%)	3 (20.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	1 (6.7%)	3 (25.0%)	4 (8.2%)
Poor	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.0%)
None	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100%)	1 (6.7%)	1 (8.3%)	1 (2.0%)

^a Minor surgery also includes invasive procedures.

The majority of ratings were "excellent" (≥ 81.3% in each VWD type). Only 2 procedures in 1 subject with Type 3 VWD received an overall efficacy rating of "none," and 1 procedure in 1 subject with Type 2 VWD received an overall efficacy rating of "poor."

The total dose of Alphanate[®] received over the entire perioperative period of the retrospective study is summarized in **Table 12**.

Table 12: Alphanate[®] Received (VWF:RCO) by Category of Procedure

	A-SD/HT
Number of patients	39
Number of surgical procedures	61
Mean number of infusions	5.9
Median number of infusions per surgical procedure (range)	3 (1-27)

15. REFERENCES

- Eyster, M.E. Hemophilia: A Guide for the Primary Care Physician. Postgrad Med 1978; 64:75-81.
- Shanbrom, E., Thelin, M. Experimental Prophylaxis of Severe Hemophilia with a Factor VIII Concentrate. JAMA 1969; 208(9):1853-1856.
- Levine, P.H. Hemophilia and Allied Conditions. In: Brain, M.C. ed. Current Therapy in Hematology-Oncology: 1983-1984, New York: BC Decker, 1983, pp. 147-152.
- Rizza, C.R., Biggs, R. Blood Products in the Management of Haemophilia and Christmas Disease. In: Poller, L., ed. Recent Advances in Blood Coagulation, Boston: Little Brown, 1969, pp. 179-195.
- Hathaway, W.E., Mahasandana, C., Clarke, S. Alteration of Platelet Function After Transfusion in Hemophilia. Proc 14th Ann Mtg, Am Soc Hematol 1971, Abstracts, 58, No. 88.
- Kasper, C.K. Incidence and Course of Inhibitors Among Patients with classic Hemophilia. Thromb Diath Haemorrh 1973; 30:263-271.
- Rizza, C.R., Biggs, R. The Treatment of Patients Who Have Factor VIII Antibodies. Br J Haematol 1973; 24:65-82.
- Roberts, H.R., Knowles, M.R., Jones, T.L., McMillan, C. The Use of Factor VIII in the Management of Patients with Factor VIII Inhibitors. In: Brinkhous, K.M., ed. Hemophilia and New Hemorrhagic States, International Symposium, New York, University of North Carolina Press, 1970, pp. 152-163.

- Federici, A.B., Bardo, F., Caracciolo, C., Mancuso, G., Mazzucconi, M.G., Musso, R., Schinco, P.C., Targhetta, R., Mannucci, P.M. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi[®]) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 8:761-767.
- Federici, A.B. Management of von Willebrand disease with FVIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005;16(Suppl 1):S17-S21.
- Mannucci, P.M. How I treat patients with von Willebrand disease. Blood 2001; 97:1915-1919.
- Mannucci, P.M. Treatment of von Willebrand's Disease. N Engl J Med 2004;351:683-694.
- Mannucci, P.M. Venous Thromboembolism in von Willebrand Disease. Thromb Haemost 2002; 88:378-379.
- Markis, M., Colvin, B., Gupta, V., Shields, M.L., Smith, M.P. Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with von Willebrand Disease. Thromb Haemost 2002; 88:387-388.
- Biggs, R. Jaundice and Antibodies Directed Against Factors VIII and IX in Patients Treated for Haemophilia or Christmas Disease in the United Kingdom. Br J Haematol 1974; 26:313-329.
- Kasper, C.K., Kipnis, S.A. Hepatitis and Clotting Factor Concentrates. JAMA 1972; 221:510.
- Mannucci, P.M., Federici, A.B. Antibodies to von Willebrand Factor in von Willebrand Disease. In: Aledort L.M., Hoyer L.W., Reiserer J.M., White II, G.C. eds. Inhibitors to coagulation factor in the 1990s, 1995, Plenum Press, pp. 87-92.
- Data on file at Grifols Biologicals Inc.
- Fujimura, Y., Titani, K., Holland, L.Z., Roberts, J.R., Kostel, P., Ruggeri, Z.M., Zimmerman, T.S. A heparin-binding domain of human von Willebrand factor: Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262(4):1734-1739.
- Horowitz, B. Investigations into the Application of Tri (n-Butyl) Phosphate/Detergent Mixture to Blood Derivatives. In: Morgenthaler, J.-J. ed. Viral Inactivation in Plasma Products, Karger, 1989, 56:83-96.
- Edwards, C.A., Piet, M.P.J., Chin, S., Horowitz, B. Tri (n-Butyl) Phosphate/Detergent Treatment of Licensed Therapeutic and Experimental Blood Derivatives. Vox Sang 1987; 52:53-59.
- Hershgold, E.J. Properties of Factor VIII (Antihemophilic Factor). In: Spaet, T.H., ed. Progress in Hemostasis and Thrombosis, Grune and Stratton Publisher, 1974, 2:99-139.
- Ashenhurst, J.B., Langehenning, P.L., Seeler, R.A. Early Treatment of Bleeding Episodes with 10 U/Kg of Factor VIII. Blood 1977;50:181.
- Hoyer, L.W. The Factor VIII complex: Structure and function. Blood 1981; 58:1-13.
- Meyer, D., and Girma, J.-P. von Willebrand factor: Structure and function. Thromb Haemost 1983; 70:99-104.
- Mannucci, P.M., Chediak, J., Hanna, W., Byrnes, J.J., Kessler, C.M., Ledford, M., Retzius, A.D., Kapelan, B.A., Gallagher, P., Schwartz, R.S., and the Alphanate Study Group. Treatment of von Willebrand's Disease (VWD) with a high purity factor VIII concentrate. Dissociation between correction of the bleeding time (BT), VWF multimer pattern, and treatment efficacy. Blood 1999; 94 (Suppl 1, Part 2 of 2):98b.

16. HOW SUPPLIED/STORAGE AND HANDLING

Alphanate[®] is supplied in sterile, lyophilized form in a single dose vial with a vial of diluent (Sterile Water for Injection, USP), a Mix2Vial[™] filter transfer set for use in administration. International unit activity of Factor VIII and VWF:RCO are stated on the carton and label of each vial.

It is available in the following potencies, and the product is also color coded based upon assay on the carton and vial label as follows:

Potency	NDC	Assay Color Code
250 IU FVIII/5 mL single dose vial	68516-4601-1	LOW in gray box
500 IU FVIII/5 mL single dose vial	68516-4602-1	MID in blue box
1000 IU FVIII/10 mL single dose vial	68516-4603-2	HIGH in red box
1500 IU FVIII/10 mL single dose vial	68516-4604-2	SUPER HIGH in black box

Storage

Alphanate[®] should be stored at temperatures between 2 and 8 °C. Do not freeze to prevent damage to diluent vial. Alphanate[®] may be stored at room temperature not to exceed 30 °C for up to 2 months. When removed from refrigeration, record the date removed on the space provided on the carton.

17. PATIENT COUNSELING INFORMATION

Patients should be informed of the early symptoms and signs of hypersensitivity reaction, including hives, generalized urticaria, chest tightness, dyspnea, wheezing, faintness, hypotension, and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physician and/or seek immediate emergency care, depending on the severity of the reaction, if these symptoms occur. It is recommended that the lot number of the vials used be recorded when Alphanate[®] is administered.

17.1 Thromboembolic Events

Thromboembolic events have been reported in von Willebrand Disease patients receiving Antihemophilic Factor/von Willebrand Factor Complex replacement therapy, especially in the setting of known risk factors for thrombosis.^{13,14} Early reports might indicate a higher incidence in females. In addition, endogenous high levels of FVIII have also been associated with thrombosis but no causal relationship has been established. In all VWD patients in situations of high thrombotic risk receiving coagulation factor replacement therapy, caution should be exercised and antithrombotic measures should be considered. See also **WARNINGS AND PRECAUTIONS (5.1)**.

17.2 Infections

Because Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate[®] is made from pooled human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Stringent procedures designed to reduce the risk of adventitious agent transmission have been employed in the manufacture of this product, from the screening of plasma donors and the collection and testing of plasma, through the application of viral elimination/reduction steps such as solvent detergent and heat treatment in the manufacturing process. Despite these measures, such products can still potentially transmit disease; therefore, the risk of infectious agents cannot be totally eliminated. The physician should weigh the risks and benefits of the use of this product and should discuss these with the patient. See also **WARNINGS AND PRECAUTIONS (5.2)**.

17.3 Inhibitor Formation

Some patients develop inhibitors to Factor VIII. These inhibitors are circulating antibodies (i.e., globulins) that neutralize the procoagulant activity of Factor VIII. No studies have been conducted with Alphanate[®] to evaluate inhibitor formation. Therefore, it is not known whether there are greater, lesser or the same risks of developing inhibitors due to the use of this product than there are with other antihemophilic factor preparations. Patients with these inhibitors may not respond to treatment with Antihemophilic Factor/von Willebrand Factor Complex (Human), or the response may be much less than would otherwise be expected; therefore, larger doses of Antihemophilic Factor/von Willebrand Factor Complex (Human) are often required. The management of bleeding in patients with inhibitors requires careful monitoring, especially if surgical procedures are indicated.⁵⁻⁸ See also **WARNINGS AND PRECAUTIONS (5.3)**.

Manufactured and Distributed by:

Grifols Biologicals Inc.

Los Angeles, CA 90032, U.S.A.

U.S. License No. 1694

DATE OF REVISION: March 2010